Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.

Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, Mok YM, Lim BP, Gwee KP.

CNS Drugs. 2015 Aug;29(8):695-712. doi: 10.1007/s40263-015-0267-6. Review.

PMID:
26293743
2.

Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.

Edwards SJ, Hamilton V, Nherera L, Trevor N.

Health Technol Assess. 2013 Nov;17(54):1-190. doi: 10.3310/hta17540. Review.

3.

Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model.

Ramsberg J, Asseburg C, Henriksson M.

PLoS One. 2012;7(8):e42003. doi: 10.1371/journal.pone.0042003. Epub 2012 Aug 2.

4.

Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand.

Prukkanone B, Vos T, Bertram M, Lim S.

Value Health. 2012 Jan-Feb;15(1 Suppl):S3-8. doi: 10.1016/j.jval.2011.11.009.

5.
6.

Impact of treatment success on health service use and cost in depression: longitudinal database analysis.

Byford S, Barrett B, Despiégel N, Wade A.

Pharmacoeconomics. 2011 Feb;29(2):157-70. doi: 10.2165/11537360-000000000-00000.

PMID:
21142289
7.

The role of quetiapine extended release in the treatment of bipolar depression.

Cristancho MA, Thase ME.

Adv Ther. 2010 Nov;27(11):774-84. doi: 10.1007/s12325-010-0067-9. Epub 2010 Sep 10. Review.

PMID:
20835785
8.

Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.

Snedecor SJ, Botteman MF, Schaefer K, Sarocco P, Barry N, Pickard AS.

J Ment Health Policy Econ. 2010 Mar;13(1):27-35.

PMID:
20571180
9.

Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.

Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, Reinecke MA, March JS.

J Am Acad Child Adolesc Psychiatry. 2009 Jul;48(7):711-20. doi: 10.1097/CHI.0b013e3181a2b319.

PMID:
19465880
10.

Escitalopram versus other antidepressive agents for depression.

Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006532. doi: 10.1002/14651858.CD006532.pub2. Review.

11.

Pharmacoeconomics of antidepressants in moderate-to-severe depressive disorder in Colombia.

Machado M, Lopera MM, Diaz-Rojas J, Jaramillo LE, Einarson TR; Universidad Nacional de Colombia Pharmacoeconomics Group.

Rev Panam Salud Publica. 2008 Oct;24(4):233-9.

PMID:
19133171
12.

Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.

Sava FA, Yates BT, Lupu V, Szentagotai A, David D.

J Clin Psychol. 2009 Jan;65(1):36-52. doi: 10.1002/jclp.20550.

PMID:
19051275
13.

[Consumption of antidepressants in Chile from 1992 to 2004].

Jirón M, Machado M, Ruiz I.

Rev Med Chil. 2008 Sep;136(9):1147-54. doi: /S0034-98872008000900009. Epub 2008 Nov 12. Spanish.

14.
15.

Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.

Tournier M, Moride Y, Crott R, du Fort GG, Ducruet T.

J Affect Disord. 2009 May;115(1-2):160-6. doi: 10.1016/j.jad.2008.07.004. Epub 2008 Aug 9.

PMID:
18694602
16.

A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.

Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.

Health Technol Assess. 2008 May;12(14):iii-iv, ix-60.

17.

Cost-effectiveness of depression treatment for adolescents.

Norquist G, McGuire TG, Essock SM.

Am J Psychiatry. 2008 May;165(5):549-52. doi: 10.1176/appi.ajp.2008.08020316. No abstract available.

PMID:
18450932
18.

Cost-effectiveness of treatments for adolescent depression: results from TADS.

Domino ME, Burns BJ, Silva SG, Kratochvil CJ, Vitiello B, Reinecke MA, Mario J, March JS.

Am J Psychiatry. 2008 May;165(5):588-96. doi: 10.1176/appi.ajp.2008.07101610. Epub 2008 Apr 15.

PMID:
18413703
19.

Folate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial.

Roberts SH, Bedson E, Hughes D, Lloyd K, Menkes DB, Moat S, Pirmohamed M, Slegg G, Thome J, Tranter R, Whitaker R, Wilkinson C, Russell I.

BMC Psychiatry. 2007 Nov 15;7:65. Erratum in: BMC Psychiatry. 2009;9. doi: 10.1186/1471-244X-9-14. Menkes, David B [added]; Thome, Johannes [added].

20.

A budget-impact and cost-effectiveness model for second-line treatment of major depression.

Malone DC.

J Manag Care Pharm. 2007 Jul;13(6 Suppl A):S8-18.

PMID:
17874482
Items per page

Supplemental Content

Loading ...
Write to the Help Desk